Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies Article

Xu, Y, Kolesar, JM, Schaaf, LJ et al. (2009). Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies . CANCER CHEMOTHERAPY AND PHARMACOLOGY, 63(6), 1073-1082. 10.1007/s00280-008-0826-3

Open Access

cited authors

  • Xu, Y; Kolesar, JM; Schaaf, LJ; Drengler, R; Duan, W; Otterson, G; Shapiro, C; Kuhn, J; Villalona-Calero, MA

sustainable development goals

authors

publication date

  • May 1, 2009

published in

keywords

  • CAMPTOTHECIN
  • COLORECTAL-CANCER
  • CPT-11
  • Celecoxib
  • DNA TOPOISOMERASE-I
  • DT-DIAPHORASE
  • INDUCIBLE CHEMORESISTANCE
  • INHIBITION
  • Irinotecan
  • Life Sciences & Biomedicine
  • Mitomycin C
  • Modulation
  • NF-KAPPA-B
  • Oncology
  • Pharmacokinetic
  • Pharmacology & Pharmacy
  • Phase I
  • RANDOMIZED-TRIAL
  • Science & Technology
  • THERAPY

Digital Object Identifier (DOI)

publisher

  • SPRINGER

start page

  • 1073

end page

  • 1082

volume

  • 63

issue

  • 6